The objective of this study was to compare the safety and effi cacy of atosiban and ritodrine in the treatment of threatened preterm labour (TPL) and to analyse the predictive factors of preterm delivery. We retrospectively sampled data on 380 women hospitalised for TPL (24 – 35 weeks ’ gestation), in our clinic between 2004 and 2007. All were subjected to tocolysis with ritodrine and/or atosiban. Data were analysed using R (version 2.12.1), considering p 0.05 as signifi cant. We had 69 women treated with atosiban, 242 treated with ritodrine and 69 treated with ritodrine changed for atosiban, if adverse eff ects occurred. In the multivariate logistic regression, the use of atosiban vs ritodrine does not play any role in delaying delivery after 48 h or 7 days, whereas the cervical change at the digital examination, high contractions pre/post-therapy ratio, pPROM, cervical length and fi bronectin result as predictive factors for both delivery before 48 h or 7 days. Maternal adverse drug eff ects were signifi cantly more frequent in patients treated with ritodrine, and one single case of pulmonary oedema was observed. We found fewer side-eff ects in the atosiban than in the ritodrine group and no diff erence in effi cacy. Moreover, the most predictive factors for preterm delivery were fi bronectin test, pPROM, digital vaginal examination and uterine contraction persistence. We believe that predictive capacity of these tests could give the opportunity for targeting therapy and limiting drug side-eff ects and cost.

Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour.

DRIUL, Lorenza;MARCHESONI, Diego
2014-01-01

Abstract

The objective of this study was to compare the safety and effi cacy of atosiban and ritodrine in the treatment of threatened preterm labour (TPL) and to analyse the predictive factors of preterm delivery. We retrospectively sampled data on 380 women hospitalised for TPL (24 – 35 weeks ’ gestation), in our clinic between 2004 and 2007. All were subjected to tocolysis with ritodrine and/or atosiban. Data were analysed using R (version 2.12.1), considering p 0.05 as signifi cant. We had 69 women treated with atosiban, 242 treated with ritodrine and 69 treated with ritodrine changed for atosiban, if adverse eff ects occurred. In the multivariate logistic regression, the use of atosiban vs ritodrine does not play any role in delaying delivery after 48 h or 7 days, whereas the cervical change at the digital examination, high contractions pre/post-therapy ratio, pPROM, cervical length and fi bronectin result as predictive factors for both delivery before 48 h or 7 days. Maternal adverse drug eff ects were signifi cantly more frequent in patients treated with ritodrine, and one single case of pulmonary oedema was observed. We found fewer side-eff ects in the atosiban than in the ritodrine group and no diff erence in effi cacy. Moreover, the most predictive factors for preterm delivery were fi bronectin test, pPROM, digital vaginal examination and uterine contraction persistence. We believe that predictive capacity of these tests could give the opportunity for targeting therapy and limiting drug side-eff ects and cost.
File in questo prodotto:
File Dimensione Formato  
Driul2014_atosiban.pdf

non disponibili

Descrizione: pdf
Tipologia: Documento in Post-print
Licenza: Non pubblico
Dimensione 271.39 kB
Formato Adobe PDF
271.39 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11390/1043785
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact